AIMS: Oral L-arginine supplementation has been used in several studies to improve endothelium-dependent, nitric oxide (NO)-mediated vasodilation. L-Arginine treatment is hampered by extensive presystemic elimination due to intestinal arginase activity. In contrast, L-citrulline is readily absorbed and at least in part converted to L-arginine. The aim of our study was to assess this metabolic conversion and its subsequent pharmacodynamic effects. METHODS: In a double-blind, randomized, placebo-controlled cross-over study, 20 healthy volunteers received six different dosing regimes of placebo, citrulline, and arginine. Pharmacokinetic parameters (C(max), T(max), C(min), AUC) were calculated after 1 week of oral supplementation. The ratio of plasma L-arginine over asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase (arginine/ADMA ratio), urinary cyclic guanosine monophosphate (cGMP) and nitrate excretion rates, and flow-mediated vasodilation (FMD) was measured to assess pharmacodynamic effects. RESULTS: L-Citrulline dose-dependently increased AUC and C(max) of plasma L-arginine concentration more effectively than L-arginine (P < 0.01). The highest dose of citrulline (3 g bid) increased the C(min) of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121]. Moreover, urinary nitrate and cGMP were increased from 92 +/- 10 to 125 +/- 15 micromol mmol(-1) creatinine (P = 0.01, 95% CI 8, 58) and from 38 +/- 3.3 to 50 +/- 6.7 nmol mmol(-1) creatinine (P = 0.04, 95% CI 0.4, 24), respectively. No treatment improved FMD over baseline. However, pooled analysis of all FMD data revealed a correlation between the increase of arginine/ADMA ratio and improvement of FMD. CONCLUSION: Our data show for the first time that oral L-citrulline supplementation raises plasma L-arginine concentration and augments NO-dependent signalling in a dose-dependent manner.
RCT Entities:
AIMS: Oral L-arginine supplementation has been used in several studies to improve endothelium-dependent, nitric oxide (NO)-mediated vasodilation. L-Arginine treatment is hampered by extensive presystemic elimination due to intestinal arginase activity. In contrast, L-citrulline is readily absorbed and at least in part converted to L-arginine. The aim of our study was to assess this metabolic conversion and its subsequent pharmacodynamic effects. METHODS: In a double-blind, randomized, placebo-controlled cross-over study, 20 healthy volunteers received six different dosing regimes of placebo, citrulline, and arginine. Pharmacokinetic parameters (C(max), T(max), C(min), AUC) were calculated after 1 week of oral supplementation. The ratio of plasma L-arginine over asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase (arginine/ADMA ratio), urinary cyclic guanosine monophosphate (cGMP) and nitrate excretion rates, and flow-mediated vasodilation (FMD) was measured to assess pharmacodynamic effects. RESULTS:L-Citrulline dose-dependently increased AUC and C(max) of plasma L-arginine concentration more effectively than L-arginine (P < 0.01). The highest dose of citrulline (3 g bid) increased the C(min) of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121]. Moreover, urinary nitrate and cGMP were increased from 92 +/- 10 to 125 +/- 15 micromol mmol(-1) creatinine (P = 0.01, 95% CI 8, 58) and from 38 +/- 3.3 to 50 +/- 6.7 nmol mmol(-1) creatinine (P = 0.04, 95% CI 0.4, 24), respectively. No treatment improved FMD over baseline. However, pooled analysis of all FMD data revealed a correlation between the increase of arginine/ADMA ratio and improvement of FMD. CONCLUSION: Our data show for the first time that oral L-citrulline supplementation raises plasma L-arginine concentration and augments NO-dependent signalling in a dose-dependent manner.
Authors: J S Pollock; U Förstermann; J A Mitchell; T D Warner; H H Schmidt; M Nakane; F Murad Journal: Proc Natl Acad Sci U S A Date: 1991-12-01 Impact factor: 11.205
Authors: R H Böger; S M Bode-Böger; L Phivthong-ngam; R P Brandes; E Schwedhelm; A Mügge; M Böhme; D Tsikas; J C Frölich Journal: Atherosclerosis Date: 1998-11 Impact factor: 5.162
Authors: R H Böger; S M Bode-Böger; A Szuba; P S Tsao; J R Chan; O Tangphao; T F Blaschke; J P Cooke Journal: Circulation Date: 1998-11-03 Impact factor: 29.690
Authors: L Castillo; T C deRojas; T E Chapman; J Vogt; J F Burke; S R Tannenbaum; V R Young Journal: Proc Natl Acad Sci U S A Date: 1993-01-01 Impact factor: 11.205
Authors: Anna Dikalova; Judy L Aschner; Mark R Kaplowitz; Gary Cunningham; Marshall Summar; Candice D Fike Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-02-19 Impact factor: 5.464
Authors: Chad M Kerksick; Colin D Wilborn; Michael D Roberts; Abbie Smith-Ryan; Susan M Kleiner; Ralf Jäger; Rick Collins; Mathew Cooke; Jaci N Davis; Elfego Galvan; Mike Greenwood; Lonnie M Lowery; Robert Wildman; Jose Antonio; Richard B Kreider Journal: J Int Soc Sports Nutr Date: 2018-08-01 Impact factor: 5.150
Authors: Janneke M Brussee; Tsin W Yeo; Daniel A Lampah; Nicholas M Anstey; Stephen B Duffull Journal: Antimicrob Agents Chemother Date: 2015-10-19 Impact factor: 5.191
Authors: Eric T Trexler; Adam M Persky; Eric D Ryan; Todd A Schwartz; Lee Stoner; Abbie E Smith-Ryan Journal: Sports Med Date: 2019-05 Impact factor: 11.136
Authors: D Winnica; L G Que; C Baffi; H Grasemann; K Fiedler; Z Yang; E Etling; K Wasil; S E Wenzel; B Freeman; F Holguin Journal: Clin Exp Allergy Date: 2016-10-04 Impact factor: 5.018